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Abstract
Cancer patients have an increased risk of developing venous thromboembolism (VTE), a condi-
tion that is associated with increased morbidity and mortality. Although risk assessment tools 
have been developed, it is still very challenging to predict which cancer patients will suffer 
from VTE. The scope of this review is to summarize and discuss studies focusing on the link 
between genetic alterations and risk of cancer- associated thrombosis (CAT). Thus far, classical 
risk factors that contribute to VTE have been tried as risk factors of CAT, with low success. In 
support, hypercoagulant plasma profiles in patients with CAT differ from those with only VTE, 
indicating other risk factors that contribute to VTE in cancer. As germline mutations do not 
significantly contribute to elevated risk of VTE, somatic mutations in tumors may significantly 
associate with and contribute to CAT. As it is very time- consuming to investigate each and every 
mutation, an unbiased approach is warranted. In this light we discuss our own recent unbiased 
proof- of- principle study using RNA sequencing in isolated colorectal cancer cells. Our work has 
uncovered candidate genes that associate with VTE in colorectal cancer, and these gene pro-
files associated with VTE more significantly than classical parameters such as platelet counts, 
D- dimer, and P- selectin levels. Genes associated with VTE could be linked to pathways being 
involved in coagulation, inflammation and methionine degradation. We conclude that tumor cell- 
specific gene expression profiles and/or mutational status has superior potential as predictors 
of VTE in cancer patients.
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Essentials
• The mechanisms behind cancer-associated thrombosis are poorly understood.
• The link between mutations and risk of cancer-associated thrombosis is discussed.
• Genetic profiling of tumors from patients may elucidate the underlying mechanisms.
• An unbiased molecular profiling could form a diagnostic tool to predict thrombosis in cancer.
1  | INTRODUCTION
The relationship between cancer and venous thromboembolism 
(VTE) is well established, however the underlying pathogenic 
mechanism has remained elusive. Among all patients with VTE, ap-
proximately one in five is diagnosed with cancer, whereas cancer 
patients have a four- to seven- fold increased risk for a VTE event.1-
3 Furthermore, cancer- associated thrombosis (CAT) contributes to 
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high morbidity and mortality, with VTE being the second cause of 
death—after cancer, itself.4,5 Besides the “classical” patient- related 
factors like age, ethnicity and prior history of VTE, several other 
risk factors intrinsic to cancer that may contribute to CAT have 
been addressed, such as higher tumor grade, metastatic disease, 
and cancer type. Cancer types may be classified into those that 
confer a high risk (pancreas, brain), moderate risk (lung, colon) and 
low risk (prostate, breast) of VTE.6,7 In addition, cancer treatment 
such as surgery and chemotherapy further increases the risk of 
VTE.8,9
In order to select those patients that are at (high) risk for VTE 
and those who might benefit from thromboprophylaxis, devel-
opment of an accurate prediction models is key. These models 
will undoubtedly become more accurate as we learn more on the 
mechanisms underlying CAT. Although extensive research has 
been performed on finding biomarkers that predict VTE in cancer 
patients, the focus in most studies was on coagulation factors—
either in terms of expression or genetic variants—and mediators. 
In this review we will discuss some of these risk factors, focusing 
mainly on potential tumor- derived biomarkers. Furthermore, we 
will present future directions that may be taken to increase the 
accuracy of CAT prediction models.
2  | RISK A SSESSMENT TOOL S
Over the years, several risk assessment tools have been developed 
to estimate the risk of CAT,6,10-12 but unfortunately, the accuracy of 
such tools is very low.9,13,14 The main limitations of these risk as-
sessment tools are: (a) while performing better in large cohort stud-
ies these tools are unable to predict CAT at the individual level, (b) 
these models are not developed for specific cancer types, (c) they 
underperform when used to predict risk of recurrence VTE, and (iv) 
they poorly predict increased risk of mortality. Inclusion of variables 
classically associated with VTE, such as platelet counts, D- Dimer and 
P- selectin levels, moderately improves power of such models. At the 
same time, it should be noted that these plasma- derived biomarkers 
are sensitive to circumstances like inflammation, surgery and chem-
otherapy, and therefore introduce a wide variability in their plasma 
concentrations.
The most recently developed risk score, TiC- Onco—that also in-
cludes genetic risk factors—showed a positive predictive value of up 
to 37%, which is only an incremental increase over the predictive 
values obtained after using the Khorana score that correctly pre-
dicted VTE in only 22% of the CAT patients.15
The main reason why progress in understanding and predicting 
CAT is slow is the fact that many investigators extrapolate classi-
cal VTE risk factors to CAT patients, with addition of a few extra 
risk factors related to cancer. However, a recent publication indi-
cates that cancer patients with VTE have different plasma profiles 
compared to patients with VTE only.16 In this study, the authors 
measured concentrations of 31 plasma proteins using multiplexed 
targeted proteomics. Here, the authors were able to identify and 
cluster 17 out of 25 cancer patients with VTE compared to healthy 
controls and patients with VTE only, based on their plasma protein 
levels. This research indicates that a “unique fingerprint” protein 
profile in CAT patients, and a combination of coagulation fac-
tors that differs from those in patients with VTE only, should be 
considered. Unfortunately, the authors do not explain what this 
unique barcode in their plasma is. Yet, while these findings need 
to be validated in other cohorts this approach holds promise for 
the future.
3  | TISSUE FACTOR
A protein that is considered the center of cancer- associated throm-
bosis is tissue factor (TF) as it plays a role in both tumor progres-
sion and VTE. Since the association and putative role of TF in CAT 
is extensively investigated and reviewed17-21 we will only briefly 
summarize the most important findings. TF is the activator of the 
extrinsic coagulation pathway, ultimately resulting in fibrin degrada-
tion and platelet activation. TF overexpression has been associated 
with reduced survival, increased angiogenesis, migration, and inva-
sive capacity of tumor cells in a number of cancer types (previously 
reviewed elsewhere19,20). At present, only a handful of studies have 
investigated the clinical association between tumor- expressed TF 
and the incidence of VTE. In pancreatic cancer, the risk of VTE was 
increased four- fold in patients with high tumor TF expression when 
compared to those with low TF levels.22 Furthermore, in a relatively 
small cohort, consisting of 32 ovarian cancer patients, TF expression 
showed a correlation with the incidence of thrombosis and D- dimer 
levels.23 However, not all studies confirm a link between TF and VTE. 
In a prospective study on non- small cell lung carcinoma (n = 39), TF 
expression did not associate with increased risk of VTE.24 Similarly, in 
a study by Thaler et al., TF expression in brain tumors did not associ-
ate with increased VTE events.25 Thus, high TF expression in tumors 
does not lead to VTE in cancer patients per se, while associations 
between TF and VTE risks may very well be cancer- type specific.
Stubborn as scientists may be—including ourselves—the search 
for a “black and white” association between TF and VTE in cancer 
patients continued. The majority of research attention then focused 
on associations between VTE- and TF- positive extracellular vesicles 
(TF+ EVs). Tumor cells may shed EVs into the bloodstream as a conse-
quence of cellular activation or cell death. As EVs typically contain sim-
ilar membrane- bound proteins as their mother cell, EVs can possess 
procoagulant activity that may contribute to VTE. Preclinical mouse 
models have demonstrated that TF+ EVs are being shed from pancre-
atic cancer cells into the bloodstream, mediating platelet activation 
and thrombus formation.26-28 Unfortunately, a relationship between 
circulating TF+ EVs and VTE in a clinical setting was only established 
in pancreatic cancer patients, while no correlation was found in other 
moderate- to- high- risk groups such as brain, colorectal, or lung cancer 
patients.29,30 Although we would have wished to consider TF the cen-
ter of cancer- associated thrombosis, no evidence has been found to 
consider TF (EVs) as the one and only risk factor or biomarker.
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4  | HOST- SPECIFIC GENETICS
Mutations in coagulation related genes are known contributors of 
VTE in non- cancer patients. Therefore, initial studies investigating 
CAT have focused on these “classical” targets. Factor V Leiden—a 
genetic variant that is resistant to inactivation by activated protein 
C—confers an increased risk of VTE with an odds ratio of 3.49 in the 
healthy population.31 While some studies suggest a two- to five- fold 
increased risk of VTE in cancer patients with Factor V Leiden,32-34 
other cohort studies were unable to confirm this association.35-37 
Similarly, polymorphisms in other coagulation- related genes, such 
as FII G20210A, FIII - 603A/G, FIII +5466A>G, FXIII Val34Leu, and 
methylenetetrahydrofolate reductase C667T, showed no effect 
on VTE incidence in patients with and without cancer.34-36,38,39 
Altogether, these studies suggest that host- specific mutations and 
SNPs in coagulation factors are not main contributors of VTE in can-
cer patients, and therefore should not be considered as potential 
biomarkers.
In recent years, studies have also addressed involvement of un-
suspected gene variants as contributors to VTE in cancer patients. 
One example is a study in which colorectal cancer patients with a 
β3- integrin rs3809865 A/A genotype were shown to have an in-
creased risk of VTE compared to colorectal cancer patients with an 
A/T or T/T genotype.40 Although the causality between this gene 
variant and CAT remains unknown, the authors speculate that this 
variant might lead to an increased expression of β3- integrin, as this 
genotype is less susceptible to microRNA- mediated downregulation. 
To our knowledge, rs3809865 A/A–dependent β3- integrin expres-
sion on endothelial cells and platelets has not been investigated. 
Moreover, the risk of VTE in non- cancer patients with this genotype 
is unknown. Thus, while it is tempting to speculate on a link between 
β3- integrin rs3809865 A/A and an increased risk of VTE in patients 
with cancer, this hypothesis cannot be validated.
Others have reported synergistic effects of germline polymor-
phisms and chemotherapy—an anticancer strategy that increases 
the risk of VTE six- fold—on the incidence of VTE in cancer patients.8 
Specifically, patients with a polymorphism in the promoter region 
of vascular endothelial growth factor, at location - 1154, appear to 
have a four- fold reduced risk of VTE (OR = 0.26) while treated with 
standard chemotherapies, like fluorouracil, irinotecan, or platinum- 
based drugs.41 Gastrointestinal cancer patients carrying the tumor 
necrosis factor alpha - 857 C/T polymorphism or a five- loci CTGGG 
haplotype (- 863C/- 857T/- 376G/- 308G/- 238G) are at increased risk 
of VTE during fluorouracil- based chemotherapy.42
5  | TUMOR- SPECIFIC GENETICS
Tumor cells contain an abundance of mutations and show different 
gene expression profiles when compared to their untransformed 
counterparts. It is now believed that both somatic mutations and 
tumor cell–specific gene profiles might contribute to increased risk 
of CAT.
A number of studies have shown that mutational status associ-
ates with TF expression. For instance, in colorectal cancer TF ex-
pression is upregulated via MAPK and PI3K signaling pathways due 
to mutations in K- ras and loss of the tumor suppressor p53.19,20 In 
glioblastoma, TF expression is regulated in an EGFR- dependent 
manner together with loss of PTEN.21 In support, the link between 
elevated TF levels and mutations in K- ras, PTEN and p53 were con-
firmed in tumor specimens derived from patients with non- small cell 
lung cancer.22,23 Although TF expression does not necessarily asso-
ciate with a high risk of VTE, as discussed above, it may very well be 
that K- ras, p53, EGFR, and PTEN mutations have an impact on VTE 
(summarized in Table 1).
In a multicenter retrospective study cohort (activating) mutations 
in K- ras—specifically in codons 12 and 13—associated with a two- 
fold increased risk of VTE in metastatic colorectal cancer patients 
when compared to those patients bearing a wild- type K- ras in colon 
tumors (OR = 2.21). Interestingly, when VTE was separated into pa-
tients with DVT or PE the odds ratio changed to 2.62 and 1.36, re-
spectively. Investigation of the seven most common K- ras mutation 
types did not reveal a specific variant that associates with VTE, sug-
gesting that hyperactivation of K- ras in general contributes to VTE in 
metastatic colorectal cancer patients.43 A retrospective case- control 
study in lung cancer confirmed the association between K- ras muta-
tion and increased VTE risk (OR = 2.67).44 Mechanistic studies have 
given more insight in the consequences of K- ras activation on tumor 
progression. K- ras promotes several signaling pathways, resulting in 
increased angiogenesis, inflammation, and invasion.45,46 Moreover, 
elevated levels of inflammatory mediators, eg, IL- 6 and IL- 8, may be 
found in tumor cells harboring a K- ras mutation.45 Interestingly, in-
creased IL- 6 and IL- 8 levels in plasma are associated with increased 
risk of VTE in non- cancer patients.47 It should, however, be noted 
that no correlations were found between interleukins and VTE in the 
Vienna Cancer and Thrombosis Study cohort,48 except for patients 
with pancreatic cancer. This might be attributed to the relatively low 
incidence of VTE in the cohort (7.2%) and that plasma was collected 
prior to cancer- related therapy, ruling out contributions of surgery 
and/or chemotherapy. Overall, this suggests that mutational status 
of K- ras might serve as a potential biomarker and might serve as an 
upstream regulator of CAT.
Unfortunately, associations between EGFR and VTE in cancer 
are less obvious. Although tumor specimens of high- grade astroc-
ytroma (a specific type of brain cancer) showed a strong correlation 
between TF and EGFR expression coinciding with an increase in in-
travascular thrombosis in the tumor, it was not examined if these 
patients indeed had (a)symptomatic VTE.49 In contrast with these 
data, a retrospective study showed a decreased hazard risk of VTE in 
EGFR- mutation bearing lung adenocarcinoma patients.50 Yet, in an-
other retrospective case- control study, no association of VTE events 
in EGFR mutated patients was found when compared to those with-
out.44 This latter group included all types of non- small cell lung car-
cinoma, with lung carcinoma constituting 72% and 57% of case and 
control patients, respectively. The majority of VTE events in lung 
cancer is associated with non- small cell lung carcinoma.51
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Another mutation found in 5% of the tumors from non- small 
cell lung carcinoma patients is chromosomal rearrangement of 
anaplastic lymphoma kinase (ALK). The first study on this muta-
tion and its link with CAT showed an increased risk of VTE.52 In 
a cohort of Canadian lung adenocarcinoma patients, VTE was di-
agnosed in over 40% of patients with ALK rearrangements, and 
in an Israeli validation cohort 28% of the patients with ALK re-
arrangements had VTE. In this latter cohort, patients were not 
screened for asymptomatic VTE diagnosis, which could explain 
the lower incidence rate. In contrast, in a retrospective study that 
consisted of a similar group size a trend of decreased VTE risk in 
patients with ALK rearrangement in lung adenocarcinoma was 
determined.50 Thus, ALK mutational status as a marker or even 
a driver for increased VTE risk in non- small cell lung carcinoma 
remains controversial.
In brain cancer, aggressive glioblastoma frequently harbor the 
wild- type variant of isocitrate dehydrogenase 1 or 2 (IDH1/2),53 
while somatic point mutations in IDH1/2 are associated with less 
aggressive behavior and less necrosis.54,55 A recent study has in-
vestigated whether patients with wild- type IDH1/2 glioblastoma 
are more likely to develop VTE. Interestingly, patients harbor-
ing IDH1/2 mutations did not develop VTE neither in a discov-
ery nor in a validation cohort, both consisting of approximately 
150 patients.56 Furthermore, only 2% of the tumors with IDH1/2 
mutation showed intratumoral microthrombi versus 86% in wild- 
type IDH1/2 tumors. This association could be linked to reduced 
TF expression in the tumors and circulating procoagulant active 
TF+ EVs. Therefore, IDH1/2 mutation might be an interesting bio-
marker to predict which cancer patients have a decreased risk of 
VTE.
6  | UNBIASED SCREEN FOR RISK FACTORS 
IN CAT
It is a time- consuming effort to identify all mutations in tumors 
and to link them individually to risks of VTE in cancer. Therefore, 
we have previously proposed to screen—in an unbiased manner—
tumor gene expression profiles and/or mutations that associate 
with VTE in cancer patients. In a proof- of- principle study we 
showed that it is feasible to link tumor- specific gene expression 
profiles with VTE in colorectal cancer patients.57 In this study RNA 
from isolated tumor cells was subjected to next generation RNA 
sequencing, making it possible to compare expression profiles in 
tumor cells from colorectal cancer patients with VTE compared 
to colorectal cancer patients without VTE. Tumors from CAT pa-
tients had different expression profiles that involved pathways re-
lated to coagulation, inflammation, homocysteine production, and 
TABLE  1 Clinical studies on mutational status and cancer- associated thrombosis
Cancer Cohort type
Cohort 
size Tumor type
Gene of 
interest Outcome Remarks Ref
Colorectal Retrospective 172 Metastatic 
colorectal 
cancer
K- ras OR = 2.21 Bevacizumab independent; 
Multicenter
Ades et al. 2015
Lung Retrospective 
case- control
159 Non- small cell 
lung carcinoma
K- ras OR = 2.67 Corrales- 
Rodriguez et al. 
2014
EGFR OR = 0.99
Retrospective 293 Lung 
adenocarci-
noma
EGFR HR = 0.46 TKI treatment reduces VTE 
risk
Davidsson et al. 
2017
ALK HR = 0.61 (ns)
Discovery 55 Lung 
adenocarci-
noma
ALK 41.8% VTE All patients had ALK 
rearrangement; included 
patients with VTE history 
and thromboprofylaxis
Zer et al. 2017
Validation 43 Non- small cell 
lung carcinoma
ALK 27.9% VTE All patients had ALK 
rearrangement; included 
patients with VTE history 
and thromboprofylaxis
Brain Discovery 169 Glioma IDH1/2 0% VTE Wild- type: 25.5% VTE; 
microthrombi in 85.5% WT 
vs. 1.9% in mutant
Unruh et al. 
2016
Validation 148 Glioma IDH1/2 0% VTE Wild- type: 29.5% VTE; 
microthrombi in 90.4% WT 
vs. 5.9% in mutant
ALK, anaplastic lymphoma kinase; HR, hazard ratio; IDH1/2, isocitrate dehydrogenase 1 or 2; OR, odds ratio; TKI, tyrosine kinase inhibitor; VTE, venous 
thromboembolism.
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liver- and retinoid X receptor function (Table 2). In addition, tumor 
specimens from CAT patients displayed a pro- inflammatory state 
and elevated fibrin deposition levels. Stratification of patients 
for timing of VTE (ie, VTE before colorectal cancer diagnosis or 
VTE around the time of colorectal cancer diagnosis), suggested 
that time of a VTE event influenced the set of observed gene ex-
pression profiles. Particularly, gene expression profiles suggested 
a pro- inflammatory status in patients with VTE prior to colorec-
tal cancer diagnosis and altered cellular metabolism in patients 
included in the group that experienced VTE around the time of 
colorectal cancer diagnosis. This may suggest that altered expres-
sion profiles within the tumor are affected by cancer treatment 
like surgery or chemotherapy. Hence, we assume that treatment- 
related CAT and CAT in the absence of such treatment have differ-
ent etiologies, and this warrants further investigation.
This study opens up new possibilities in improving our under-
standing of the pathophysiological mechanism of CAT, to better 
treat CAT, and to improve CAT prediction models. It would be of 
interest to further investigate whether single or co- expression of 
the top 3 genes as identified in the patient group experiencing VTE 
before colorectal cancer diagnosis (REG4, SPINK4, and SERPINA1) 
could serve as a strong predictor of VTE in colorectal cancer pa-
tients. Additionally, these three genes encode secretable proteins 
and therefore future work is required to study if plasma levels could 
also serve as prognostic biomarkers.58-60 Furthermore, it would be 
interesting to investigate if there is a relationship and/or synergism 
with mutational status of K- ras, as this is already associated with 
CAT in colorectal cancer.43 Finally, future work may demonstrate 
that there is a link between the expression profiles in CAT and differ-
ent subtypes of colon cancer,61 as Magnus et al. previously reported 
glioblastoma subtype- specific phenotypes and altered coagulation- 
related genes. Such identification may allow for personalized treat-
ment of colorectal cancer patients to prevent CAT.
Significant upregulation of REG4 was detected both in patients 
with VTE before, as well as around colorectal cancer diagnosis. 
Overexpression of Reg4 is associated with tumor progression, me-
tastasis and reduced survival.62-64 As mentioned before, risk of CAT 
increases dramatically in patients experiencing metastasis compared 
to non- metastatic cancer patients.65-67 Tumor cells must gain cancer 
stem cell properties and should undergo epithelial- to- mesenchymal 
transition, for successful metastasis.68,69 In the bloodstream pro-
coagulant functions rescue the circulating tumor cell from immune 
attack and shear stress, which additionally supports metastasis.70-72 
Of note, REG4 is associated with cancer stemness and metasta-
sis,73,74 suggesting that Reg4- dependent metastasis may be another 
mechanism leading to CAT. Unfortunately, thus far, no (genetic) re-
ports have been published on the mechanism linking metastasis to 
increased risk of VTE. We believe that rather than the metastatic le-
sion itself, circulating tumor cells contribute to VTE, as they: (i) pos-
sess procoagulant activity, (ii) may consist of large clumps of multiple 
cells, and (iii) are found in thrombi.75,76 Although, studies on this par-
ticular topic are rather inconclusive, Mego et al. recently reported in 
a US- based retrospective study that 9% of (metastatic) breast cancer 
patients experienced CAT with circulating tumor cells detectable, 
whereas patients without detectable circulating tumor cells had no 
VTE.77 Discrimination of circulating tumor cells into epithelial or 
TABLE  2 Expression profile and 
associated canonical pathways in 
colorectal cancer patients with VTE 
before or around diagnosis
−1 year ≤ Cancer diagnosis −3 ≤  Cancer diagnosis ≤ +3 Months
P value P value
Top canonical pathways
LXR/RXR activation 1,39E- 03 Methionine degradation I 9,79E- 03
FXR/RXR activation 1,51E- 03 Cysteine biosynthesis III 1,07E- 02
Atherosclerosis signalling 1,53E- 03 Superpathway of methionine 
degradation
1,67E- 02
Coagulation system 1,63E- 02 Glutamate receptor 
signalling
2,64E- 02
Thyroid cancer signalling 1,86E- 02 Autophagy 2,86E- 02
−1 year ≤ Cancer diagnosis −3 ≤  Cancer diagnosis ≤ +3 Months
Genes AvgLog2FC
Adjusted P 
value Genes AvgLog2FC
Adjusted P 
value
Gene expression profile
 REG4 7,3 1,18E- 09 GBP4 3,9 3,07E- 07
 SPINK4 6,7 1,63E- 05 XKR9 6,2 1,08E- 06
 SERPINA1 6,8 5,45E- 04 CTSE 7,2 1,87E- 06
 SLITRK6 4,0 6,44E- 03 AHCYL2 2,8 2,55E- 05
 SBSPON 4,2 8,49E- 02 GRM8 - 5,1 2,77E- 05
 DEFA 4,3 1,13E- 01 REG4 5,5 1,49E- 04
Table adjusted from Ünlü et al.57
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mesenchymal- like circulating tumor cells in a Slovakian cohort with 
116 early breast cancer patients showed no differences, with only 
one patient with mesenchymal- like circulating tumor cells eventually 
developing VTE.78 Therefore, future research directions may include 
genetic profiling, using RNAseq, of circulating tumor cells, primary 
and metastatic tumors in patients with and without CAT.
7  | CONCLUSION
Despite over 150 years of effort to elucidate mechanisms behind 
CAT, or to accurately predict which cancer patients have an in-
creased risk of CAT, research has made only incremental steps for-
ward. With the most recently developed risk assessment tools only 
37% cases of CAT can be predicted, which is—in our opinion—not 
accurate enough. Therefore, scientists should change their view 
on the mechanisms behind VTE in cancer patients. Classical risk 
factors of VTE cannot be extrapolated to cancer patients, nor do 
(mutations in) coagulation- related genes significantly contribute to 
CAT. So far, germline variants have only been shown to affect VTE 
risk during chemotherapy. Thus, we believe that understanding the 
mechanism behind CAT comes from genetic profiling of tumors. At 
present, only mutations in K- ras in colon and lung cancer show an 
association with increased risk of VTE, while IDH1/2 mutations are 
associated with a decrease in VTE risk in glioblastoma patients. As 
it is time consuming to investigate the role of every gene in CAT 
one by one searching for genes that associate with CAT an unbiased 
manner may be more appropriate. This should ultimately lead to the 
discovery of novel biomarkers that potentially serve as a diagnos-
tic tool. Furthermore, it will also give more insight in the upstream 
biological processes that provoke a hypercoagulant state, leading 
to VTE. We furthermore recommend assessing genetic profiles in 
each cancer (sub)type separately, since different genetic events that 
associate with CAT may be dependent on processes that are cancer 
type- specific.
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